Citations

Showing 10 of 108094 citations.

Can I Ask a Question About URiM Awards That I Don’t Know the Answer to? Designing an Award for Underrepresented Medical Education Researchers
Zaidi, Zareen , Sukhera, Javeed , Kulasegaram, Kulamakan , Young, Meredith , Fung, Cha-Chi, LaDonna, Kori A. , Sewell, Justin L. , Schumacher, Daniel J. , Hunderfund, Andrea N. Leep , Balmer, Dorene F. , Park, Yoon Soo

Mayo Clinic

Academic Medicine | August 10, 2022 | Volume: 97 | Issue: 11S | Pages: S4-S7

10.1097/acm.0000000000004902 | PMID 35947477 Get It

Meaningful Equity, Diversity, and Inclusion (EDI) efforts may be stymied by concerns about whether proposed initiatives are performative or tokenistic. The purpose of this project was to analyze discussions by the Research in Medical Education (RIME) Program Planning committee about how best to recognize and support underrepresented in medicine (URiM) researchers in medical education to generate lessons learned that might inform local, national, and international actions to implement meaningful EDI initiatives. Ten RIME Program Planning Committee members and administrative staff participated in a focus group held virtually in August 2021. Focus group questions elicited opinions about “if and how” to establish a URiM research award. The focus group was recorded, transcribed, and thematically analyzed. Recognition of privilege, including who has it and who doesn’t, underpinned the focus group discussion, which revolved around 2 themes: (1) tensions between optics and semantics, and (2) potential unintended consequences of trying to level the medical education playing field. The overarching storyline threaded throughout the focus group discussion was intentionality. Focus group participants sought to avoid performativity by creating an award that would be meaningful to recipients and to career gatekeepers such as department chairs and promotion and tenure committees. Ultimately, participants decided to create an award that focused on exemplary Equity, Diversity, and Inclusion (EDI) scholarship, which was eventually named the “RIME URiM Research Award.” Difficult but productive conversations about EDI initiatives are necessary to advance underrepresented in medicine (URiM) scholarship. This transparent commentary may trigger further critical conversations.
Factors Associated With Physical Activity Levels in Patients With Breast Cancer
Marell, Paulina S. , Herrmann, Joerg , D’Andre, Stacy D, Cheville, Andrea , Barksdale, Toure, Loprinzi, Charles L. , Ruddy, Kathryn J. , Cheville, Andrea L , Ruddy, Kathryn J , Vierkant, Robert A. , Olson, Janet E. , Larson, Nicole , LeBrasseur, Nathan K. , Barksdale, Touré, Couch, Fergus J.

Mayo Clinic

The Oncologist | August 10, 2022 | Volume: 27 | Issue: 10 | Pages: e811-e814

10.1093/oncolo/oyac159 | PMID 35946834 Get It

Abstract Physical activity (PA) is associated with improvement in breast cancer treatment-related symptoms and survival, yet most breast cancer survivors do not meet national PA guidelines. This study aimed to identify characteristics of participants that were associated with an increased likelihood of meeting PA guidelines. Adults with breast cancer seen at Mayo Clinic (Rochester, MN) were surveyed regarding their PA participation, and those who self-reported at least 150 minutes of moderate and/or strenuous aerobic PA weekly on average were considered to be “meeting guidelines”. Three thousand participants returned PA data. Younger age, completion of the survey 7-12 years after diagnosis, absence of recurrence, no bilateral mastectomy, absence of metastatic disease, and lower BMI at the time of survey completion were associated with PA participation (P < .05 in univariate and multivariate analyses). Findings were similar when a threshold of 90 minutes was applied. These results may inform the development of targeted PA-facilitating interventions.
Imaging of Bowel Ischemia: An Update, From the AJR Special Series on Emergency Radiology
Olson, Michael C. , Bach, Corrie R. , Wells, Michael , Andrews, James C. , Welle, Christopher L. , Fidler, Jeff L. , Khandelwal, Ashish , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | August 10, 2022 | Volume: 220 | Issue: 2 | Pages: 173-185

10.2214/ajr.22.28140 | PMID 35946859 Get It

Change in Body Mass Index and Attributable Risk of New-Onset Hypertension Among Obese Living Kidney Donors
Reed, Rhiannon D. , McLeod, M. Chandler, MacLennan, Paul A. , Pittman, Sydney E., Maynor, Andrew G., Stanford, Luke A., Baker, Gavin , Silkensen, John R., Segev, Dorry L. , Lewis, Cora E. , Segev, Dorry L , Kumar, Vineeta , Schinstock, Carrie A. , Roll, Garrett Richard , Orandi, Babak John , Locke, Jayme E.

Mayo Clinic

Annals of Surgery | August 10, 2022 | Volume: 278 | Issue: 1 | Pages: e115-e122

10.1097/sla.0000000000005669 | PMID 35946818 Get It

Objective: To examine whether body mass index (BMI) changes modify the association between kidney donation and incident hypertension. Background: Obesity increases hypertension risk in both general and living kidney donor (LKD) populations. Donation-attributable risk in the context of obesity, and whether weight change modifies that risk, is unknown. Methods: Nested case-control study among 1558 adult LKDs (1976–2020) with obesity (median follow-up: 3.6 years; interquartile range: 2.0–9.4) and 3783 adults with obesity in the Coronary Artery Risk Development in Young Adults (CARDIA) and Atherosclerosis Risk in Communities (ARIC) studies (9.2 y; interquartile range: 5.3–15.8). Hypertension incidence was compared by donor status using conditional logistic regression, with BMI change investigated for effect modification. Results: Overall, LKDs and nondonors had similar hypertension incidence [incidence rate ratio (IRR): 1.16, 95% confidence interval (95% CI): 0.94–1.43, P=0.16], even after adjusting for BMI change (IRR: 1.25, 95% CI: 0.99–1.58, P=0.05). Although LKDs and nondonors who lost >5% BMI had comparable hypertension incidence (IRR: 0.78, 95% CI: 0.46–1.34, P=0.36), there was a significant interaction between donor and >5% BMI gain (multiplicative interaction IRR: 1.62, 95% CI: 1.15–2.29, P=0.006; relative excess risk due to interaction: 0.90, 95% CI: 0.24–1.56, P=0.007), such that LKDs who gained weight had higher hypertension incidence than similar nondonors (IRR: 1.83, 95% CI: 1.32–2.53, P<0.001). Conclusions: Overall, LKDs and nondonors with obesity had similar hypertension incidence. Weight stability and loss were associated with similar hypertension incidence by donor status. However, LKDs who gained >5% saw increased hypertension incidence versus similar nondonors, providing support for counseling potential LKDs with obesity on weight management postdonation.
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
Bewicke‐Copley, Findlay , Korfi, Koorosh , Araf, Shamzah, Hodkinson, Brendan P. , Kumar, Emil , Cummin, Thomas , Ashton‐Key, Margaret , Barrans, Sharon, Hoppe, Suzan van, Burton, Cathy , Elshiekh, Mohamed , Rule, Simon , Crosbie, Nicola, Clear, Andrew , Calaminici, Maria , Runge, Hendrik F.P. , Hills, Robert K. , Sha, Chulin , Painter, Daniel , Smith, Alexandra , Naresh, Kikkeri N. , Westhead, David R. , Steele, Andrew J. , Hodson, Daniel J. , Balasubramanian, Sriram , Runge, Hendrik , Scott, David W , Nagano, Ai , Davies, Andrew , Painter, Daniel , Smith, Alexandra , Gribben, John G. , Westhead, David R , Okosun, Jessica , Steele, Andrew , Hodson, Daniel J , Johnson, Peter , Wang, Jun , Fitzgibbon, Jude , Naresh, Kikkeri N , Scott, David W. , Rimsza, Lisa M. , Menon, Geetha, Davies, John R., Davies, Andrew , Johnson, Peter , Fitzgibbon, Jude

Mayo Clinic

Blood Advances | August 10, 2022 | Volume: 7 | Issue: 5 | Pages: 845-855

10.1182/bloodadvances.2022007536 | PMID 35947123 Get It

Abstract Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short of providing a consistent relapse-specific genetic signature. In our study, we have focused attention on the changes in GEP accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo patients with DLBCL. COO remained stable from diagnosis to relapse in 80% of patients, with only a single patient showing COO switching from activated B-cell–like (ABC) to germinal center B-cell–like (GCB). Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC–DLBCLs derived from relapse-associated genes that defined clinically distinct high- and low-risk subgroups in ABC–DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of &lt;60-year–old patients with superior PFS and OS treated with ibrutinib–R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.
Oral montelukast reduces number and frequency of aphthous ulcers: a retrospective review
Hwang, Angelina , Campbell, Elliott H. , Sartori‐Valinotti, Julio C. , Hwang, Angelina S

Mayo Clinic

International Journal of Dermatology | August 10, 2022 | Volume: 62 | Issue: 7 | Pages: No page available

10.1111/ijd.16393 | PMID 35947073 Get It

How do I warm HPC(A) products to maximize cell viability in the setting of cold agglutinin disease?
Krull, Ashley , Thompson, Thomas , Strasburg, Dustin J. , DiGuardo, Margaret , Jacob, Eapen K., Strasburg, Dustin, Thompson, Thomas Zachary

Mayo Clinic

Transfusion | August 10, 2022 | Volume: 62 | Issue: 10 | Pages: 1942-1947

10.1111/trf.17038 | PMID 35946488 Get It

AbstractBackgroundHigh titers of cold agglutinins jeopardize the quality of an apheresis product meant for autologous or allogeneic transplant. Management of transplant patients with cold agglutinin disease (CAD) is often experience‐based and under reported, yet decisions must be made quickly to optimize product management and patient outcomes. There remains a lack of data quantifying cell recovery and viability when using various warming methodologies.Study Design and MethodsTo expand the published experimental data on this subject, our human cellular therapy lab compared cellular recoveries and viabilities after manipulation of cryopreserved apheresis products through various warming methodologies: (1) extended warming in a water bath, (2) warming via blood warmer and infusion pump, and (3) warming in a water bath followed by infusion pump as a control to assess potential shear stress effects.ResultsThe presented studies demonstrate that all methods of product warming produce the same rates of recovery of total and viable cells across vital cell types prior to patient administration. Statistically, use of an extended water bath protocol provided a marginal benefit in recovery of total nucleated cells, though this effect is diminished when products are held for an extended period to simulate a delay in administration.DiscussionThese results can inform decisions to improve patient care and minimize product manipulation and loss. Centers are encouraged to use this information to guide proactive measures to establish a standard operating procedure to manage CAD cases.
Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis
Hussain, Salman , Singh, Ambrish , Antony, Benny , Klugarová, Jitka , Murad, M. Hassan , Jayraj, Aarthi S , Langaufová, Alena , Klugar, Miloslav , Murad, M Hassan , Klugar, Miloslav

Mayo Clinic

Journal of Clinical Medicine | August 10, 2022 | Volume: 11 | Issue: 16 | Pages: 4675

10.3390/jcm11164675 | PMID 36012913 Get It

Evidence from preclinical studies suggests a preventive effect of proton pump inhibitors (PPIs) in preeclampsia. Recently, several epidemiological studies have described a conflicting association between the use of PPIs during pregnancy and preeclampsia risk. This study aimed to evaluate the association between PPI use and the risk of preeclampsia. We searched databases, including MEDLINE, Embase, Scopus, Web of Science Core Collection, Emcare, CINAHL, and the relevant grey literature from inception until 13 September 2021. Studies reporting the preeclampsia risk with the use of PPIs were eligible for inclusion. Literature screening, data extraction, and the risk of bias assessment were performed independently by two investigators. Random-effect meta-analysis was performed to generate relative risks (RR) and 95% confidence intervals (CI). The risk of preeclampsia and preterm preeclampsia among women receiving PPIs during pregnancy were the primary outcomes of interest. This meta-analysis comprised three studies involving 4,877,565 pregnant women, of whom 119,017 were PPI users. The included studies were judged to have a low risk of bias. The risk of preeclampsia among pregnant women who received PPIs anytime during pregnancy was significantly increased (RR 1.27 (95% CI: 1.23–1.31)), although the increase was trivial in absolute terms (2 per 1000). The subgroup analysis revealed that the risk was increased in each of the three trimesters. The risk of preterm preeclampsia among pregnant women receiving PPIs anytime during pregnancy was not significantly increased (RR 1.04 (95% CI: 0.70–1.55)). The certainty evaluated by GRADE in these estimates was low. PPI use may be associated with a trivial increase in the risk of preeclampsia in pregnant women. There is no evidence supporting that PPI use decreases the risk of preeclampsia or preterm preeclampsia.
Molecular Testing for Diagnosis of Early Lyme Disease
Theel, Elitza S.

Mayo Clinic

American Journal of Clinical Pathology | August 10, 2022 | Volume: 158 | Issue: 3 | Pages: 325-326

10.1093/ajcp/aqac080 | PMID 35946458 Get It

Risk of Dementia Associated With Atrial Cardiopathy: The ARIC Study
Johansen, Michelle C. , Wang, Wendy , Zhang, Michael J. , Knopman, David S. , Ndumele, Chiadi E. , Mosley, Thomas H. , Selvin, Elizabeth , Shah, Amil M. , Solomon, Scott D. , Selvin, Elizabeth , Mosley, Thomas H. , Knopman, David S. , Zhang, Michael , Ndumele, Chiadi , Gottesman, Rebecca F , Chen, Lin Y , Selvin, Elizabeth , Johansen, Michelle C , Shah, Amil , Solomon, Scott David , Gottesman, Rebecca F. , Chen, Lin Y.

Mayo Clinic

Journal of the American Heart Association | August 10, 2022 | Volume: 11 | Issue: 16 | Pages: No page available

10.1161/jaha.121.025646 | PMID 35946474 Get It

Background The contribution of atrial cardiopathy to dementia risk is uncharacterized. We aimed to evaluate the association of atrial cardiopathy with incident dementia and potential mediation by atrial fibrillation (AF) and stroke. Methods and Results We conducted a prospective cohort analysis of participants in the ARIC (Atherosclerosis Risk in Communities) study attending visit 5 (2011–2013). We used Cox regression to determine the association between atrial cardiopathy and risk of dementia. Structural equation modeling methods were used to determine potential mediation by AF and/or stroke. Atrial cardiopathy was defined if ≥1 of the following at visit 5: P‐wave terminal force >5000 mV·ms in ECG lead V1, NT‐proBNP (N‐terminal pro–brain natriuretic peptide) >250 pg/mL or left atrial volume index ≥34 mL/m 2 by transthoracic echocardiography. We repeated our analysis necessitating ≥2 markers to define atrial cardiopathy. The prevalence of atrial cardiopathy was 34% in the 5078 participants (mean age 75 years, 59% female, 21% Black adults), with 763 participants developing dementia. Atrial cardiopathy was significantly associated with dementia (adjusted HR, 1.35 [95% CI, 1.16–1.58]), with strengthening of the effect estimate when necessitating ≥2 biomarkers (adjusted HR, 1.54 [95% CI, 1.25–1.89]). There was an increased risk of dementia among those with atrial cardiopathy when excluding those with AF (adjusted HR, 1.31 [95% CI, 1.12–1.55]) or stroke (adjusted HR, 1.28 [95% CI, 1.09–1.52]). The proportion of the effect mediated by AF was 4% ( P =0.005), and 9% was mediated by stroke ( P =0.048). Conclusions Atrial cardiopathy was significantly associated with an increased risk of dementia, with only a small percent mediation of the effect by AF or stroke.